Danielle Lam

Danielle Lam

Auto-generated profile, based on publicly available information

Danielle Lam

Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK Department of Gastroenterology, Sir Charles Gairdner Hospital , Perth, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2023 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
CKChristina Kapizioni
Christina Kapizioni
RDRofaida Desoki
Rofaida Desoki
DLDanielle Lam
Danielle Lam
KBKarthiha Balendran
Karthiha Balendran
EAEman Al-Sulais
Eman Al-Sulais
TRTim Raine
Tim Raine
Background and Aims: This study compares the effectiveness of different biologic therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world data from a large cohort with long exposure. Methods: Demographic, disease, treatment, and outcome data were retrieved for patients in the UK IBD BioResource. Effectiveness of treatment was based on persistence free of discontinuation or failure, analysed by Kaplan–Meier survival analysis with inverse probability of treatment weighting to adjust for differences between groups. Results: In total, 13 222 evaluable patients received at least one biologic. In ulcerative colitis [UC] first-line vedolizumab [VDZ] demonstrated superior effectiveness over 5 years compared to anti-tumour necrosis factor [anti-TNF] agents [p = 0.006]. VDZ was superior to both infliximab [IFX] and adalimumab [ADA] after ADA and IFX failure respectively [p < 0.001 and p < 0.001]. Anti-TNF therapy showed similar effectiveness when used as first-line treatment, or after failure of VDZ. In Crohn’s disease [CD] we found significant differences between first-line treatments over 10 years [p = 0.045], with superior effectiveness of IFX compared to ADA in perianal CD. Non-anti-TNF biologics were superior to a second anti-TNF after first-line anti-TNF failure in CD [p = 0.035]. Patients with UC or CD experiencing TNF failure due to delayed loss of response or intolerance had superior outcomes when switching to a non-anti-TNF biologic, rather than a second anti-TNF. Conclusions: We provide real-world evidence to guide biologic selection and sequencing in a range of common scenarios. Our findings challenge current guidelines regarding drug selection after loss of response to first anti-TNF treatment.